Pearl Becomes First Dental AI Company Cleared by FDA for Both 2D and 3D Imaging

Audio By Carbonatix

LOS ANGELES--(BUSINESS WIRE)--May 27, 2025--

Pearl, the global leader in dental AI solutions, today announced that it has received FDA 510(k) clearance for Second Opinion® 3D, making Pearl the first and only dental AI company with FDA-cleared solutions for both 2D and 3D dental radiologic image analysis.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250527510723/en/

Pearl Becomes First Dental AI Company Cleared by FDA for Both 2D and 3D Imaging

With this new clearance, Pearl’s Second Opinion® platform extends its AI capabilities to cone beam computed tomography (CBCT) imaging, enabling automated identification of critical anatomical structures—including dentition, maxilla, mandible, inferior alveolar canal and mental foramen (IAN), maxillary sinus, nasal space, and airway—in 3D scans.

“Pearl’s mission has always been to deliver the most advanced and clinically trusted AI solutions in dentistry,” said Ophir Tanz, founder and CEO of Pearl. “Becoming the first company to achieve FDA clearance for both 2D and 3D radiologic analysis isn’t just a milestone for us—it’s a milestone for dentistry.”

Second Opinion® 3D is designed to assist dental professionals in reviewing CBCT scans with greater speed, accuracy, and clarity. It empowers clinicians with instant AI-powered visualizations that support more precise diagnostics and treatment planning across specialties, including implantology, orthodontics, oral surgery, and airway management.

The FDA clearance follows extensive bench performance testing, in which Second Opinion® 3D demonstrated high segmentation accuracy across all targeted anatomical structures. Dice Similarity Coefficient scores exceeded clinical thresholds for every category, confirming both safety and effectiveness.

This clearance builds on Pearl’s track record as a regulatory leader in dental AI. The company’s original Second Opinion® platform remains the most widely deployed FDA-cleared solution for chairside AI pathology detection in 2D radiographs. With the addition of 3D capabilities, Pearl now delivers the only FDA-cleared platform capable of supporting comprehensive radiologic review across both major dental imaging modalities.

About Pearl

Pearl is an AI-driven company committed to enhancing patient care in dentistry. Founded in 2019 by a team with decades of experience developing successful, enterprise-grade computer vision solutions, Pearl introduced the first-ever FDA-cleared AI capable of reading and instantly identifying diseases in dental x-rays. With regulatory clearance in 120 countries, Pearl's AI assists dentists in making precise clinical decisions and effectively communicating with patients, thereby transforming the dental care experience worldwide. As dentistry’s global AI leader, Pearl is committed to the ongoing innovation of robust, accessible AI tools that improve patient health outcomes and build greater trust in dental medicine. To request a demo, please visit hellopearl.com/getdemo

View source version on businesswire.com:https://www.businesswire.com/news/home/20250527510723/en/

CONTACT: Media Contact

Kate Gundry

[email protected]

617-797-5174

KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: HEALTH FDA TECHNOLOGY HEALTH TECHNOLOGY DENTAL RADIOLOGY ARTIFICIAL INTELLIGENCE

SOURCE: Pearl

Copyright Business Wire 2025.

PUB: 05/27/2025 10:40 AM/DISC: 05/27/2025 10:39 AM

http://www.businesswire.com/news/home/20250527510723/en